Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: Meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials

Luigi Celio, Erminio Bonizzoni, Emilio Bajetta, Silvia Sebastiani, Tania Perrone, Matti S. Aapro

Research output: Contribution to journalArticle

Abstract

Purpose: Data from two randomized trials, evaluating a single-day regimen of palonosetron plus dexamethasone against emesis due to moderately emetogenic chemotherapy, were assessed for the impact of age on outcome in a pooled sample of women receiving anthracycline and/or cyclophosphamide (AC)-containing chemotherapy. Methods: Chemo-naïve breast cancer patients randomized to receive palonosetron (0.25 mg) plus dexamethasone (8 mg IV) on day 1 of chemotherapy (n = 200), or the same regimen followed by oral dexamethasone (8 mg) on days 2 and 3 (n = 205), were included in the analysis. The primary endpoint was complete response (CR: no vomiting and no rescue anti-emetics) in the 5-day study period. The effect of the 1-day regimen and age (

Original languageEnglish
Pages (from-to)565-573
Number of pages9
JournalSupportive Care in Cancer
Volume21
Issue number2
DOIs
Publication statusPublished - Feb 2013

Keywords

  • AC-containing chemotherapy
  • Breast cancer
  • CINV
  • Dexamethasone
  • Meta-analysis
  • Palonosetron

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: Meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials'. Together they form a unique fingerprint.

  • Cite this